Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,501–4,600 of 15,747
Westrop, S. J., Whitaker, H., Powell, A. A., Power, L., Whillock, C., Campbell, H., Simmons, R., Warrener, L., Ramsay, M. E., Ladhani, S. N., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.038 · Cited by 30
Hibino, M., Uryu, K., Takeda, T., Kunimatsu, Y., Shiotsu, S., Uchino, J., Hirai, S., Yamada, T., Okada, A., Hasegawa, Y., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.05.015 · Cited by 22
“This is largely due to phase 3 trials of the vaccines, approved by the European Medicines Agency and the United States Food and Drug Administration, only including healthy individuals or those with stable chronic diseases and excluding patients with cancer being actively treated.(7,8) Currently, immune checkpoint inhi…”
BackgroundCOVID-19 clinical presentation, management, and epidemiology: a concise compendium
Maison, D. P., Tasissa, H., Deitchman, A. N., Peluso, M. J., Deng, Y., Miller, F. D., Henrich, T. J., & Gerschenson, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1498445 · Cited by 35
Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?
Hromić‐Jahjefendić, A., Barh, D., Uversky, V. N., Aljabali, A. A. A., Tambuwala, M. M., Alzahrani, K. J., Alzahrani, F. M., Alshammeri, S., & Lundstrom, K. H. (2023) · Vaccines · doi:10.3390/vaccines11020208 · Cited by 23
“21 cases per 100,000 persons [19] in comparison to 19–56 cases per 100,000 persons in the US and Europe [194], one case of a patient with a premorbid subclinical sleep disturbance that developed a clinically severe case of type 1 narcolepsy was reported after vaccination with the BNT162b2 vaccine [3].”
BackgroundResultFröhlich, G. M., de Kraker, M. E. A., Abbas, M., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.1.2001848 · Cited by 21
“However, vaccination appears to be the most efficacious preventive strategy with a conferred 95% protection against the wildtype virus [12].”
BackgroundCao, H., Mai, J., Zhou, Z. P., Li, Z., Duan, R. C., Watt, J., Chen, Z., Bandara, R. A., Li, M., Ahn, S. K., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00723-0 · Cited by 23
“To date, a number of vaccines have been evaluated in phase III clinical trials including the mRNA vaccines from PfizerBioNTech [22] and Moderna [23], the ChAd vaccine from AstraZeneca [24], and the rAd26 and rAd5 vaccines produced and tested in Russia [25].”
MethodCoulon, P.-G. A., Prakash, S., Dhanushkodi, N. R., Srivastava, R., Zayou, L., Tifrea, D. F., Edwards, R. A., Figueroa, C. J., Schubl, S. D., Hsieh, L. L., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343716 · Cited by 21
Bliźniewska-Kowalska, K. M., Halaris, A. E., Wang, S.-C., Su, K., Maes, M. H. J., Berk, M., & Gałecki, P. (2021) · Medical Science Monitor · doi:10.12659/msm.932220 · Cited by 26
Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
Bessen, C., Plaza‐Sirvent, C., Simsek, A., Bhat, J., Marheinecke, C. S., Urlaub, D., Bonowitz, P., Buße, S., Schumann, S., Blanco, E. V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049070 · Cited by 24
“Particularly, the novel mRNA vaccines show high efficacy and are well tolerated (16, 17, 50).”
BackgroundWei, J., Matthews, P. C., Stoesser, N. E., Diamond, I. D., Studley, R., Rourke, E. D., Cook, D., Bell, J. I., Newton, J. N., Farrar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31495-x · Cited by 26
“5%] previously infected) contributed 43,163 antibody measurements ≥28 days post-first dose, median (IQR) [range] 1 (1-2) [1-3] measurements per participant.”
BackgroundPresumed Recurrent MEWDS following Covid-19 Vaccination
Xu, Y., & Shen, W. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.1985524 · Cited by 21
“Previous studies have reported only mild or moderate adverse events following the Covid-19 vaccine.(2,3) MEWDS was first described by Jampol in 1984, which clinically presents in young,(4) myopic women with unilateral visual blurring and photopsia.”
BackgroundSEIR Model to address the impact of face masks amid COVID‐19 pandemic
Maged, A., Ahmed, A., Haridy, S., Baker, A. W., & Xie, M. (2022) · Risk Analysis · doi:10.1111/risa.13958 · Cited by 23
Gemmati, D., Longo, G., Gallo, I., Silva, J. A., Secchiero, P., Zauli, G., Hanau, S., Passaro, A., Pellegatti, P., Pizzicotti, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1028081 · Cited by 24
Influenza Virus and SARS-CoV-2 Vaccines
Sandor, A., Sturdivant, M. S., & Ting, J. P. ‐. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001287 · Cited by 23
Artificial Intelligence in battling infectious diseases: A transformative role
Li, C., Ye, G., Jiang, Y., Wang, Z., Yu, H., & Yang, M. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29355 · Cited by 26
“As the number of drug ‐ like small molecules is essentially infinite as large as ~10 60 , 73,76 and possibly larger, given that typical antibiotics may not be traditionally drug ‐ like, 74 a major benefit of ML approaches is that they can virtually screen compound libraries at a scale (>10 9…”
BackgroundGaborit, B., Fernandes, S., Loubet, P., Ninove, L., Dutour, A., Cariou, B., Coupaye, M., Clément, K., Czernichow, S., Carette, C., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155412 · Cited by 24
HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine
Ragone, C., Meola, S., Fiorillo, P. C., Penta, R., Auriemma, L., Tornesello, M. L., Miscio, L., Cavalcanti, E., Botti, G., Buonaguro, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.734689 · Cited by 23
“The Pfizer-BioNTech BNT162b2 vaccine is based on the entire spike glycoprotein of the virus to elicit neutralizing antibodies for blocking the interaction between the virus and the ACE-2 cellular receptor (12).”
MethodDebunking mRNA Vaccine Misconceptions—An Overview for Medical Professionals
Hitti, F. L., & Weissman, D. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.02.004 · Cited by 21
The relationship between COVID-19 vaccines and increased blood pressure: A word of caution
Buso, G., Rosei, C. A., & Muiesan, M. L. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.03.002 · Cited by 25
“domized clinical trial showing no significant correlations between vaccines and hypertension [4,5].”
Kumar, S., Saikia, D., Bankar, M., Saurabh, M. K., Singh, H., Varikasuvu, S. R., & Maharshi, V. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00429-1 · Cited by 26
Ferreira, L. S., Canton, O., Lopes, R., Poloni, S., Sudbrack, V., Borges, M. E., Franco, C. F. J., Marquitti, F. M. D., de Moraes, J. C., Veras, M. A. D. S. M., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009978 · Cited by 21
“Even BNT162b2 (Pfizer/BioNTech), which showed high efficacy against infections in the first trials [7] may provide a lower protection against new variants, as exemplified by the variant B.”
BackgroundKerr, S., Bedston, S., Bradley, D., Joy, M., Lowthian, E., Mulholland, R., Akbari, A., Hobbs, R. F., Katikireddi, S. V., de Lusignan, S., et al. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac199 · Cited by 24
Kaur, A., & Vaccari, M. (2024) · Viruses · doi:10.3390/v16030368 · Cited by 23
“Additionally, RNA vaccines have shown promise in infectious diseases, including the successful development of mRNA vaccines against COVID-19 [32–34].”
BackgroundTursi, N. J., Tiwari, S., Bedanova, N. M., Kannan, T., Parzych, E. M., Okba, N. M. A., Liaw, K., Sárközy, A., Livingston, C., Trullen, M. I., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102035 · Cited by 40
Systemic sclerosis and COVID-19 vaccines: a SPIN Cohort study
Gordon, J. K., Showalter, K., Wu, Y., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00416-1 · Cited by 21
Transient increase in plasma HIV RNA after COVID-19 vaccination with mRNA-1272
Bozzi, G., Lombardi, A., Ludovisi, S., Muscatello, A., Manganaro, L., Cattaneo, D., Gori, A., & Bandera, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.021 · Cited by 21
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.016 · Cited by 31
Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
Anjorin, A. A., Odetokun, I. A., Nyandwi, J. B., Elnadi, H., Awiagah, S. K., Eyedo, J., Abioye, A. I., Gachara, G., Maisara, A. M., Razouqi, Y., et al. (2022) · Vaccines · doi:10.3390/vaccines10040546 · Cited by 25
SARS-CoV-2: An Update on Genomics, Risk Assessment, Potential Therapeutics and Vaccine Development
Mehmood, I., Ijaz, M., Ahmad, S., Ahmed, T., Bari, A., Abro, A., Allemailem, K. S., Almatroudi, A., & Qamar, M. T. U. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041626 · Cited by 24
Utilizing Biologics in Drug Desensitization
Yang, B. C., & Castells, M. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01052-z · Cited by 22
Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
Paetzold, J., Kimpel, J., Bates, K., Hummer, M., Krammer, F., von Laer, D., & Winner, H. (2022) · Nature Communications · doi:10.1038/s41467-022-28233-8 · Cited by 23
Vollenberg, R., Tepasse, P.-R., Kühn, J. E., Hennies, M., Strauss, M., Rennebaum, F., Schomacher, T., Boeckel, G., Lorentzen, E. U., Bokemeyer, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10010171 · Cited by 26
Small vessel vasculitis related to varicella‐zoster virus after Pfizer‐BioNTech COVID‐19 vaccine
Nastro, F. F., Fabbrocini, G., Vico, F. D., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17550 · Cited by 21
Hao, Q., Long, Y., Yang, Y., Deng, Y., Ding, Z., Yang, L., Shu, Y., & Xu, H. (2024) · Vaccines · doi:10.3390/vaccines12070717 · Cited by 27
“[114,115] and various cancer types [4,10,109].”
Grano, C., Fernandes, M., & Conner, M. T. (2022) · Psychology and Health · doi:10.1080/08870446.2021.2025374 · Cited by 23
“…pandemic situation, studies had also revealed antibodies of the sARs-CoV-2 in the breast milk of women who were vaccinated or who were positive for the virus, suggesting a potential protective effect of breastfeeding against COVID-19 (Dong et al., 2020; Pace et al., 2021; Polack et al., 2020).”
BackgroundYang, M., Dong, P., Cen, L., Shi, W., He, X., & Li, J. (2023) · The ISME Journal · doi:10.1038/s41396-023-01398-w · Cited by 23
“Common chemicals, bacterial culture and standard assays are provided in SI Materials and Methods.”
MethodNeuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review
Lotan, I., Lydston, M., & Levy, M. (2022) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001537 · Cited by 22
Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER
Ionan, A. C., Clark, J. E., Travis, J. W., Amatya, A. K., Scott, J., Smith, J. P., Chattopadhyay, S., Salerno, M. J., & Rothmann, M. D. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00483-0 · Cited by 25
“The primary efficacy endpoint was confirmed cases of COVID-19 (see protocol [25] and FDA review documents for exact definition [26]), and the primary efficacy null hypothesis was Vaccine Efficacy (VE) ≤ 30%, where VE = 100 * (1 – incidence rate ratio [IRR]).”
BackgroundTang, K., Wei, Z., & Wu, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27956 · Cited by 20
Farina, M., & Lavazza, A. (2021) · International Journal of Public Health · doi:10.3389/ijph.2021.1604036 · Cited by 23
Oliveira-Silva, J., Reis, T., Lopes, C., Batista-Silva, R., Ribeiro, R. J. T., Marques, G., Pacheco, V., Rodrigues, T., Afonso, A., Pinheiro, V. C. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.014 · Cited by 25
“This observation matches evidence regarding efficacy so far [3].”
Jilich, D., Skrzat‐Klapaczyńska, A., Fleischhans, L., Bursa, D., Antoniak, S., Balayan, T., Begovać, J., Cicic, A., Dragović, G., Goekengin, D., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13194 · Cited by 21
“In registrational trials of mRNA- based vaccines, PLWH were included, but they were not analysed separately [12,13].”
BackgroundJayagobi, P. A., Ong, C., Yeo, K. T., Lim, C. C., Seet, M. J., Kwek, L. K., Ku, C. W., Chan, J. K. Y., Mathur, M., & Chien, C. M. (2021) · medRxiv · doi:10.1101/2021.06.29.21259741 · Cited by 21
“Current approved COVID-19 vaccines in Singapore (Pfizer-BioNtech and the Moderna COVID-19 mRNA vaccines) have been found to be safe and efficacious in preventing severe disease.((1,2)) As these initial vaccine trials did not include pregnant and lactating women, Singapore’s Ministry of Health (MOH) initially cautioned…”
BackgroundMcGrath, O., & Burke, K. (2024) · The American Statistician · doi:10.1080/00031305.2024.2350445 · Cited by 41
“For example, in clinical statistics, p could represent the proportion of patients exhibiting treatment side effects; such a scenario arose in the context of COVID-19 vaccination (Polack et al., 2020).”
BackgroundHill, E. M., & Keeling, M. J. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0214 · Cited by 22
COVID-19 and Multiorgan Response: The Long-Term Impact
Harky, A., Ala'Aldeen, A., Butt, S., Duric, B., Roy, S., & Zeinah, M. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101756 · Cited by 24
“Baricitinib (85,100) Accelerate clinical improvement and reduce recovery time”
BackgroundLiu, X., Wang, S., Sun, Y., Liao, Y., Jiang, G., Sun, B., Yu, J., & Zhao, D. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105638 · Cited by 27
Wieteska, M., Szmit, S., Florczyk, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9121395 · Cited by 21
Vyhmeister, R. H., Enestvedt, C. K., VanSandt, M., et al. (2021) · Liver Transplantation · doi:10.1002/lt.26097 · Cited by 21
“In December 2020, the PfizerBioNTech (New York, NY, USA and Mainz, Germany) (BNT162b2) and Moderna (Cambridge, MA, USA) (mRNA1273) vaccines were approved by the US Food and Drug Administration under an Emergency Use Authorization based on phase 2/3 clinical trial data showing high efficacy in preventing symptomatic SA…”
BackgroundTong, R., Luo, L., Zhao, Y., Sun, M., Li, R., Zhong, J., Chen, Y., Hu, L., Li, Z., Shi, J., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2187245 · Cited by 21
“CorV [2,3] and CoronaVac [4], mRNA vaccines BNT162b2 [5] and mRNA-1273 [6], adenovirus vaccines AZD1222 [7] and Ad5-nCoV [8], and protein”
BackgroundInfluentialPersistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19
Coppeta, L., Somma, G., Ferrari, C., Mazza, A., Rizza, S., Aurilio, M. T., Perrone, S., Magrini, A., & Pietroiusti, A. (2021) · Vaccines · doi:10.3390/vaccines9090947 · Cited by 21
“Data from clinical trials demonstrate that the vaccine is safe and effective [7,12].”
BackgroundAnimal models for SARS-Cov2/Covid19 research-A commentary
Jarnagin, K., Alvarez, O., Shresta, S., & Webb, D. R. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114543 · Cited by 23
Martínez‐Baz, I., Trobajo‐Sanmartín, C., Miqueleiz, A., Casado, I., Navascués, A., Burgui, C., Ezpeleta, C., Castilla, J., Guevara, M., & the Working Group for the Study of COVID-19 in Navarra (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.5.2200337 · Cited by 29
Higher sensitivity monitoring of reactions to COVID-19 vaccination using smartwatches
Guan, G., Mofaz, M., Qian, G. L., Patalon, T., Shmueli, E., Yamin, D., & Brandeau, M. L. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00683-w · Cited by 25
Exacerbation of branch retinal vein occlusion post SARS-CoV2 vaccination
Tanaka, H., Nagasato, D., Nakakura, S., Tanabe, H., Nagasawa, T., Wakuda, H., Imada, Y., Mitamura, Y., & Tabuchi, H. (2021) · Medicine · doi:10.1097/md.0000000000028236 · Cited by 23
“With the intent of limiting the further spread of SARS-CoV-2, vaccination campaigns have been ongoing all over the world.([3]) Common reactions after vaccination include pain, redness, swelling around the injection site, fever, headache, myalgia, and fatigue.”
BackgroundInfluentialFang, Y., Li, J., Duangdany, D., Yang, L., Guo, X.-L., Phamisith, C., Yu, B., Shen, M., Luo, B., Wang, Y., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102372 · Cited by 21
Papayanni, P. G., Chasiotis, D., Koukoulias, K., Georgakopoulou, A., Iatrou, A., Gavriilaki, E., Giannaki, C., Bitzani, M., Geka, E., Tasioudis, P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab371 · Cited by 25
Research progress on non-protein-targeted drugs for cancer therapy
Zhang, Y., Lu, L., Song, F., Zou, X., Liu, Y., Zheng, X., Qian, J., Gu, C., Huang, P. C., & Yang, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02635-y · Cited by 24
Acquired aplastic anemia following SARS‐CoV ‐2 vaccination
Röth, A., Bertram, S., Schroeder, T. A., Haverkamp, T., Voigt, S., Holtkamp, C., Klump, H., Wormann, B. J., Reinhardt, H. C., & Alashkar, F. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13788 · Cited by 20
COVID-19 Compulsory Vaccination: Legal and Bioethical Controversies
Gibelli, F., Ricci, G., Sirignano, A., & Leo, D. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.821522 · Cited by 28
Retinal vascular occlusion and SARS-CoV-2 vaccination
Vujosevic, S., Limoli, C., Romano, S., Vitale, L., Villani, E., & Nucci, P. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05707-5 · Cited by 22
Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review
Kiremitler, N. B., Kemerli, M. Z., Kayacı, N., Karagöz, S., Pekdemir, S., Sarp, G., Sanduvaç, S., Önses, M. S., & Yılmaz, E. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c00181 · Cited by 21
NK cells in COVID-19—from disease to vaccination
Hammer, Q., Cuapio, A., Bister, J., Björkström, N. K., & Ljunggren, H. (2023) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiad031 · Cited by 28
Tang, K., Wu, X., Luo, Y., Wei, Z., Feng, L., & Wu, L. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.02.016 · Cited by 37
Hypertension and COVID-19: Updates from the era of vaccines and variants
Swamy, S., Koch, C. A., Hannah‐Shmouni, F., Schiffrin, E. L., Kłubo-Gwieździńska, J., & Gubbi, S. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100285 · Cited by 27
“Similarly, a two dose regimen of the Pfizer vaccine provides 95% protection against COVID-19 [60].”
Haydu, J. E., Maron, J. S., Redd, R. A., Gallagher, K., Fischinger, S., Barnes, J. A., Hochberg, E. P., Johnson, P. C., Takvorian, R. W., Katsis, K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006627 · Cited by 22
Fox, T. A., Kirkwood, A. A., Enfield, L., O'Reilly, M. A., Arulogun, S. O., D’Sa, S., O’Nions, J., Kavi, J., Vitsaras, E., Townsend, W. M., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17836 · Cited by 23
Cravedi, P., Ahearn, P. C., Wang, L., Yalamarti, T., Hartzell, S., Azzi, Y., Menon, M. C., Jain, A. V., Billah, M., Fernández-Viña, M., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021040573 · Cited by 25
Almohaya, A. M., Qari, F., Zubaidi, G. A., Alnajim, N., Moustafa, K., Alshabi, M. M., Alsubaie, F. M., Almutairi, I. M. M., Alwazna, Q., Al‐Tawfiq, J. A., et al. (2021) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2021.101595 · Cited by 22
Schuler, C. F., IV, Gherasim, C., O’Shea, K. J., Manthei, D. M., Chen, J., Zettel, C., Troost, J. P., Kennedy, A. A., Tai, A. W., Giacherio, D. A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00087-21 · Cited by 22
“All subjects who were vaccinated received either the BNT162b2 or mRNA-1273 vaccines (12, 13).”
BackgroundImmune system changes in those with hypertension when infected with SARS-CoV-2
Su, S., Chen, R., Zhang, S., Shu, H., & Luo, J. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104562 · Cited by 25
Du, X., Yada, E., Terai, Y., Takahashi, T., Nakanishi, H., Tanaka, H., Akita, H., & Itaka, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092291 · Cited by 21
Tadmor, T., Benjamini, O., Braester, A., Rahav, G., & Rokach, L. (2021) · Leukemia · doi:10.1038/s41375-021-01380-5 · Cited by 21
“In addition, most of the currently available data in terms of vaccine efficacy has been assessed and reported after a short follow-up of 7–30 days post first or second shot [1, 5].”
BackgroundBell’s palsy following COVID-19 vaccination with high CSF antibody response
Obermann, M., Krasniqi, M., Ewers, N., Fayad, J., & Haeberle, U. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05496-5 · Cited by 25
Burn, E., Roel, E., Pistillo, A., Fernández‐Bertolín, S., Aragón, M., Raventós, B., Reyes, C., Verhamme, K. M. C., Rijnbeek, P. R., Li, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34669-9 · Cited by 26
Characteristics and outcomes of adverse events after COVID‐19 vaccination
Kewan, T. Z., Flores, M., Mushtaq, K., Alwakeel, M. I., Burton, R., Campbell, J., Perry, H., Al‐Jaghbeer, M. J., & Fadel, F. A. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12565 · Cited by 20
Material Design for Next-Generation mRNA Vaccines Using Lipid Nanoparticles
Higuchi, A., Sung, T., Wang, T., Ling, Q., Kumar, S. S., Hsu, S.-T., & Umezawa, A. (2022) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2022.2106490 · Cited by 23
“CureVac’s vaccine used mRNA with normal uridine, whereas the Pfizer/BioNtech vaccine and Moderna vaccine used mRNA with PseudoU (Figure 6), which show a high efficiency of 95%.([20]) Unfortunately, the efficiency of CureVac’s vaccine is reportedly too low at 47%,([50]) although CureVac’s vaccine can be maintained for…”
BackgroundCohen, J. A., Bermel, R. A., Grossman, C. I., et al. (2022) · Multiple Sclerosis Journal · doi:10.1177/13524585211061343 · Cited by 21
A Review of the Current Status of Clinical Management of COVID-19 in the Elderly
Li, Q., & Zhao, C. (2021) · Medical Science Monitor · doi:10.12659/msm.930278 · Cited by 25
Fan, Q., Shi, J., Yang, Y., Tang, G., Jiang, M., Li, J. J., Tang, J., Li, L., Wen, X., Zhang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31693-7 · Cited by 20
“208a Mild 14/70 (20) 6/35 (17) 3/22 (14) 5/13 (38) NA Smoking history, n/N (%) 6/70 (9) 5/35 (14) 1/22 (5) 0/13 (0) NA Comorbidities, n/N (%) Hypertension 4/70 (6) 4/35 (11) 0/22 (0) 0/13 (0) NA Chronic heart disease 2/70 (3) 2/35 (6) 0/22 (0) 0/13 (0) NA Diabetes 2/70 (3) 2/35 (6) 0/22 (0) 0/13 (0) NA Liver disease 1…”
Minkner, R., Boonyakida, J., Park, E. Y., & Wätzig, H. (2022) · Electrophoresis · doi:10.1002/elps.202200079 · Cited by 23
Souza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Lima, L. B., & Montenegro, R. C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.02.203 · Cited by 23
Banach, B. B., Tripathi, P., Pereira, L. D. S., Gorman, J., Nguyen, T. D., Dillon, M., Fahad, A. S., Kiyuka, P. K., Madan, B., Wolfe, J. R., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220323 · Cited by 22
“Transient antibody expression technologies, including mRNA-based gene delivery (Kose et al., 2019; Polack et al., 2020) and vectored immunoprophylaxis (Balazs et al.”
BackgroundCoarse-Grained Simulation of mRNA-Loaded Lipid Nanoparticle Self-Assembly
Grzetic, D. J., Hamilton, N. B., & Shelley, J. C. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00216 · Cited by 27
Living with HIV and Getting Vaccinated: A Narrative Review
VITO, A. D., Colpani, A., Trunfio, M., Fiore, V., Moi, G., Fois, M., Leoni, N., Ruiu, S., Babudieri, S., Calcagno, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11050896 · Cited by 23
Toll-like Receptors in Viral Encephalitis
Gern, O. L., Mulenge, F., Pavlou, A., Ghita, L., Steffen, I., Stangel, M., & Kalinke, U. (2021) · Viruses · doi:10.3390/v13102065 · Cited by 26
Cutaneous Adverse Reactions to SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Bellinato, F., Fratton, Z., Girolomoni, G., & Gisondi, P. (2022) · Vaccines · doi:10.3390/vaccines10091475 · Cited by 20
“This was not only the first mRNA vaccine approved for human use but also the fastest formulated vaccine whose development was initiated just 11 months back (January 10, 2020), without long-term safety data [2].”
BackgroundCoronavirus infections in childhood and vaccine studies
Aygün, D., Önal, P., Apaydın, G., & Çokuğraş, H. C. (2020) · Turkish Archives of Pediatrics · doi:10.5152/turkarchpediatr.2020.20255 · Cited by 27
Zhang, R., Shin, B., Gadsden, T. M., Petrosyan, A., Vo, A. A., Ammerman, N., Sethi, S., Huang, E., Peng, A., Najjar, R., et al. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13813 · Cited by 21
History of primary-series and booster vaccination and protection against Omicron reinfection
Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Yassine, H. M., Thani, A. A. A., Al-Khatib, H. A., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh0761 · Cited by 30
Sanz‐Leon, P., Hamilton, L. H. W., Raison, S. J., Pan, A. J. X., Stevenson, N. J., Stuart, R. M., Abeysuriya, R., Kerr, C. C., Lambert, S. B., & Roberts, J. A. (2022) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0311 · Cited by 19
“For its initial vaccine roll-out, Australia used two vaccines—BNT162b2 (Pfizer–BioNTech) [3] and ChAdOx1 (Oxford–AstraZeneca) [4]—with mRNA-1273 (Moderna) [5] and NVX-CoV2373 (Novavax) [6] added to the national schedule in the final quarter of 2021.”
MethodKitagawa, Y., Imai, K., Matsuoka, M., Fukada, A., Kubota, K., Sato, M., Takada, T., Noguchi, S., Tarumoto, N., Maesaki, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27338 · Cited by 18
Murray, S. M., Barbanti, M. C., Campbell, C., Brown, A., Chen, L., Dhanapal, J., Tseu, B., Pervaiz, O., Peters, L., Springett, S., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18312 · Cited by 23
Fakih, R. O. E., Haroon, A., Alfraih, F. A., Al-Khabori, M. K., Alzahrani, M., Alhuraiji, A., Hamadah, A., AlJohani, N. I., Alahmari, B., Essa, M., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01312-y · Cited by 20
Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
Labarrere, C. A., & Kassab, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652252 · Cited by 24
Vaccine hesitancy prospectively predicts nocebo side-effects following COVID-19 vaccination
Hoffman, Y. S. G., Levin, Y., Palgi, Y., Goodwin, R. B., Ben‐Ezra, M., & Greenblatt‐Kimron, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-21434-7 · Cited by 26
“The primary division of side-effects was based on earlier research which showed that psychological factors predicted a narrow list of seven side-effects [3], out of which, three side-effects were observed in the Pfizer trials [4].”
BackgroundMcCollum, C. R., Courtney, C. M., O’Connor, N. J., Aunins, T. R., Ding, Y., Jordan, T. X., Rogers, K. L., Brindley, S. M., Brown, J. M., Nagpal, P., et al. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00510 · Cited by 18
Molica, S., Giannarelli, D., Lentini, M., Zappalà, D., Mannella, A., Loiacono, D., Gianfelici, V., Panduri, G., Gariani, I., Minchella, P., et al. (2021) · Chemotherapy · doi:10.1159/000521229 · Cited by 21
New Omicron-specific vaccines offer similar protection to existing boosters
Callaway, E. (2022) · Nature · doi:10.1038/d41586-022-02806-5 · Cited by 21
Blake, T. R., Haabeth, O. A. W., Sallets, A., McClellan, R. L., Castillo, T. J. D., Vilches-Moure, J. G., Ho, W. C., Wender, P. A., Levy, R., & Waymouth, R. M. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00019 · Cited by 23
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.